Finance

Roʻyxatlar
6MK:FRA
Merck & Co Inc
131,16 €
-0,09%
(-0,12) 1K
14-okt, 17:26:30 (GMT+2)  ·   EUR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
6MK tikeri uchun statistika yaratilmoqda...
Ochish
126,72 €
Yuqori
131,16 €
Past
126,72 €
Bozor kapitali
362,97 mlrd
Oʻrtacha hajm
423,00
Hajmi
582,00
52 haftalik eng yuqori
134,54 €
52 haftalik eng past
71,00 €
Xodimlar soni
74 ming
Ochish
126,72 €
Yuqori
131,16 €
Past
126,72 €
Bozor kapitali
362,97 mlrd
Oʻrtacha hajm
423,00
Hajmi
582,00
52 haftalik eng yuqori
134,54 €
52 haftalik eng past
71,00 €
Xodimlar soni
74 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
Merck & Co Inc haqida
CEORobert M Davis
Xodimlar soni74 ming
Asos solingan1-yan, 1891
Bosh ofislar-
Sektor-
Veb-saytmerck.com
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
17,28 mlrd
16,40 mlrd
16,29 mlrd
16,61 mlrd
Sotilgan mahsulotning tannarxi
3,74 mlrd
4,30 mlrd
3,88 mlrd
4,13 mlrd
Daromad narxi
3,74 mlrd
4,30 mlrd
3,88 mlrd
4,13 mlrd
Tadqiqot va ishlanmalarga xarajatlar
4,00 mlrd
4,00 mlrd
3,56 mlrd
9,74 mlrd
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
2,48 mlrd
2,73 mlrd
2,57 mlrd
2,78 mlrd
Operatsion xarajatlar
6,48 mlrd
6,73 mlrd
6,12 mlrd
12,52 mlrd
Jami operatsion xarajatlar
10,23 mlrd
11,02 mlrd
10,00 mlrd
16,65 mlrd
Operatsion daromad
7,05 mlrd
5,38 mlrd
6,29 mlrd
-40,00 mln
Boshqa nooperatsion daromad
-
41,00 mln
42,00 mln
59,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
6,74 mlrd
3,42 mlrd
-3,53 mlrd
-683,00 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
6,76 mlrd
4,98 mlrd
5,85 mlrd
-508,00 mln
Daromad soligʻi boʻyicha xarajat
958,00 mln
458,00 mln
709,00 mln
654,00 mln
Amaldagi soliq stavkasi
14,20%
13,39%
-20,06%
-95,75%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
5,78 mlrd
2,96 mlrd
-4,24 mlrd
-1,34 mlrd
Sof foyda marjasi
33,49%
18,07%
-26,03%
-8,04%
Har bir aksiya foydasi
2,58
2,04
-1,28
-0,13
Foizlar va investitsiyalardan olingan daromadlar
96,00 mln
69,00 mln
35,00 mln
35,00 mln
Foizlarni toʻlash xarajatlari
-327,00 mln
-411,00 mln
-479,00 mln
-525,00 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-231,00 mln
-342,00 mln
-444,00 mln
-490,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
8,15 mlrd
6,79 mlrd
7,69 mlrd
1,43 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari